Science gone translational: the OX40 agonist story

di Weinberg, Andrew D., Morris, Nicholas P., Kovacsovics-Bankowski, Magdalena, Urba, Walter J., Curti, Brendan D.
Pubblicazione 2011

Phase I study of alpha-tocopherlyoxyacetic acid in patients with advanced cancer

di Curti, Brendan D, Akporiaye, Emmanuel, Sutcliffe, Kim, Bahjat, Keith S, Koguchi, Yoshinobu, Cramer, Julie, Urba, Walter
Pubblicato in J Immunother Cancer (2015)

Development and Characterization of Recombinant Human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain

di Morris, Nicholas P., Peters, Carmen, Montler, Ryan, Hu, Hong-Ming, Curti, Brendan D., Urba, Walter J., Weinberg, Andrew D.
Pubblicazione 2007

Phase II calm extension study: Coxsackievirus A21 delivered intratumorally to patients with advanced melanoma induces immune-cell infiltration in the tumor microenvironment

di Andtbacka, Robert HI, Curti, Brendan D, Hallmeyer, Sigrun, Feng, Zipei, Paustian, Christopher, Bifulco, Carlo, Fox, Bernard, Grose, Mark, Shafren, Darren
Pubblicato in J Immunother Cancer (2015)

Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program

di Payne, Roxanne, Glenn, Lyn, Hoen, Helena, Richards, Beverley, Smith, John W, Lufkin, Robert, Crocenzi, Todd S, Urba, Walter J, Curti, Brendan D
Pubblicazione 2014

Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance

di Couey, Marcus A., Bell, R. Bryan, Patel, Ashish A., Romba, Meghan C., Crittenden, Marka R., Curti, Brendan D., Urba, Walter J., Leidner, Rom S.
Pubblicato in J Immunother Cancer (2019)

An evaluation of autologous tumor-reactive TIL generation from head and neck squamous cell cancers

di Mougdil, Tarsem, Paustian, Christopher, Feng, Zipei, Leidner, Rom, Dubay, Christopher, Curti, Brendan D, Hu, Hong-Ming, Urba, Walter, Bifulco, Carlo, Fox, Bernard, Bell, Brian
Pubblicato in J Immunother Cancer (2015)

Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma

di Feng, Zipei, Puri, Sachin, Moudgil, Tarsem, Wood, William, Hoyt, Clifford C., Wang, Chichung, Urba, Walter J., Curti, Brendan D., Bifulco, Carlo B., Fox, Bernard A.
Pubblicato in J Immunother Cancer (2015)

Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilimumab

di Koguchi, Yoshinobu, Hoen, Helena, Bambina, Shelly, Rynning, Michael, Fuerstenberg, Richard, Feng, Zipei, Fox, Bernard, Bifulco, Carlo, Curti, Brendan D, Urba, Walter, Milburn, Christina, Korman, Alan J, Bahjat, Keith S
Pubblicato in J Immunother Cancer (2015)

Autophagosome-based strategy to monitor apparent tumor-specific CD8 T cells in patients with prostate cancer

di van de Ven, Rieneke, Hilton, Traci L., Hu, Hong-Ming, Dubay, Christopher J., Haley, Daniel, Paustian, Christopher, Puri, Sachin, Urba, Walter J., Curti, Brendan D., Aung, Sandra, Fox, Bernard A.
Pubblicato in Oncoimmunology (2018)

Novel strategy to monitor apparent tumor-specific T cells in patients with cancer

di van de Ven, Rieneke, Hilton, Traci L, Dubay, Christopher J, Puri, Sachin, Hu, Hong-Ming, Leidner, Rom S, Bell, R Bryan, Urba, Walter J, Curti, Brendan D, Aung, Sandra, Fox, Bernard A
Pubblicazione 2013

Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells

di Duhen, Rebekka, Ballesteros-Merino, Carmen, Frye, Alexandra K., Tran, Eric, Rajamanickam, Venkatesh, Chang, Shu-Ching, Koguchi, Yoshinobu, Bifulco, Carlo B., Bernard, Brady, Leidner, Rom S., Curti, Brendan D., Fox, Bernard A., Urba, Walter J., Bell, R. Bryan, Weinberg, Andrew D.
Pubblicato in Nat Commun (2021)

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition

di Buchbinder, Elizabeth I., Dutcher, Janice P., Daniels, Gregory A., Curti, Brendan D., Patel, Sapna P., Holtan, Shernan G., Miletello, Gerald P., Fishman, Mayer N., Gonzalez, Rene, Clark, Joseph I., Richart, John M., Lao, Christopher D., Tykodi, Scott S., Silk, Ann W., McDermott, David F.
Pubblicato in J Immunother Cancer (2019)

Out-of-sequence Signal 3 paralyzes primary CD4(+) T cell dependent immunity

di Sckisel, Gail D., Bouchlaka, Myriam N., Monjazeb, Arta M., Crittenden, Marka, Curti, Brendan D., Wilkins, Danice E.C., Alderson, Kory A., Sungur, Can M., Ames, Erik, Mirsoian, Annie, Reddy, Abhinav, Alexander, Warren, Soulika, Athena, Blazar, Bruce R., Longo, Dan L., Wiltrout, Robert H., Murphy, William J.
Pubblicato in Immunity (2015)

Adoptive TIL in HPV-negative oral scca

di Leidner, Rom, Curti, Brendan D, Payne, Roxanne M, Urba, Walter, Bahjat, Keith S, Koguchi, Yoshinobu, Nelson, Krista, Moore, Jennifer A, Crittenden, Marka, Ying, Yedeh, Patel, Ashish, Cheng, Allen, Bui, Tuan G, Hilton, Traci, Paustian, Christopher, Puri, Sachin, Hu, Hong Ming, Bifulco, Carlo, Feng, Zipei, Bell, R Bryan, Fox, Bernard
Pubblicato in J Immunother Cancer (2015)

HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cells

di Moore, Tamson V., Scurti, Gina M., DeJong, Matthew, Wang, Siao-Yi, Dalheim, Annika V., Wagner, Courtney R., Hutchens, Kelli A., Speiser, Jodi J., Godellas, Constantine V., Fountain, Chris, Fleser, Jessica, Moudgil, Tarsem, Thomas, Mallory, Murray, David, Curti, Brendan D., Clark, Joseph I., Fox, Bernard A., Nishimura, Michael I.
Pubblicato in Mol Ther Oncolytics (2021)

Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor

di Curti, Brendan D, Koguchi, Yoshinobu, Leidner, Rom S, Rolig, Annah S, Sturgill, Elizabeth R, Sun, Zhaoyu, Wu, Yaping, Rajamanickam, Venkatesh, Bernard, Brady, Hilgart-Martiszus, Ian, Fountain, Christopher B, Morris, George, Iwamoto, Noriko, Shimada, Takashi, Chang, ShuChing, Traber, Peter G, Zomer, Eliezer, Horton, J Rex, Shlevin, Harold, Redmond, William L
Pubblicato in J Immunother Cancer (2021)

Signaling through OX40 Enhances Anti-tumor Immunity

di Jensen, Shawn M., Maston, Levi D., Gough, Michael J., Ruby, Carl E., Redmond, William L., Crittenden, Marka, Li, Yuhuan, Puri, Sachin, Poehlein, Christian H., Morris, Nick, Kovacsovics-Bankowski, Magdalena, Moudgil, Tarsem, Twitty, Chris, Walker, Edwin B., Hu, Hong-Ming, Urba, Walter J., Weinberg, Andrew D., Curti, Brendan D, Fox, Bernard A.
Pubblicazione 2010

OX40 is a potent immune stimulating target in late stage cancer patients

di Curti, Brendan D., Kovacsovics-Bankowski, Magdalena, Morris, Nicholas, Walker, Edwin, Chisholm, Lana, Floyd, Kevin, Walker, Joshua, Gonzalez, Iliana, Meeuwsen, Tanisha, Fox, Bernard A., Moudgil, Tarsem, Miller, William, Haley, Daniel, Coffey, Todd, Fisher, Brenda, Delanty-Miller, Laurie, Rymarchyk, Nicole, Kelly, Tracy, Crocenzi, Todd, Bernstein, Eric, Sanborn, Rachel, Urba, Walter J., Weinberg, Andrew D.
Pubblicazione 2013

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma

di Buchbinder, Elizabeth I., Gunturi, Anasuya, Perritt, Jessica, Dutcher, Janice, Aung, Sandra, Kaufman, Howard L., Ernstoff, Marc S., Miletello, Girald P., Curti, Brendan D., Daniels, Gregory A., Patel, Sapna P., Kirkwood, John M., Hallmeyer, Sigrun, Clark, Joseph I., Gonzalez, Rene, Richart, John M., Lutzky, Joe, Morse, Michael A., Sullivan, Ryan J., McDermott, David F.
Pubblicato in J Immunother Cancer (2016)